Trial Profile

Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome

Status: Not yet recruiting

Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Timbetasin (Primary)
Indications Dry eyes
Focus Therapeutic Use
Sponsors G-treeBNT

Most Recent Events

06 Aug 2015 Status changed from planning to not yet recruiting according to RegeneRx media release.
17 Jul 2015 According to RegeneRx media release, company has recently received an IND for this trial.
17 Feb 2015 According to a RegenRx media release, G-treeBNT filed an IND for this phase IIb/III trial in South Korea in Dec 2014, it is expected to be initiated in 2015, with results in 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com